Differential Characterization of Temozolomide-Resistant Human Glioma Cells
AbstractGlioblastoma multiforme (GBM) is the most common type of primary and malignant tumor occurring in the adult central nervous system. Temozolomide (TMZ) has been considered to be one of the most effective chemotherapeutic agents to prolong the survival of patients with glioblastoma. Many glioma cells develop drug-resistance against TMZ that is mediated by increasing O-6-methylguanine-DNA methyltransferase (MGMT) levels. The expression of connexin 43 was increased in the resistant U251 subline compared with the parental U251 cells. The expression of epithelial–mesenchymal transition (EMT)-associated regulators, including vimentin, N-cadherin, and β-catenin, was reduced in the resistant U251 subline. In addition, the resistant U251 subline exhibited decreased cell migratory activity and monocyte adhesion ability compared to the parental U251 cells. Furthermore, the resistant U251 subline also expressed lower levels of vascular cell adhesion molecule (VCAM)-1 after treatment with recombinant tumor necrosis factor (TNF)-α. These findings suggest differential characteristics in the drug-resistant GBM from the parental glioma cells. View Full-Text
Share & Cite This Article
Lai, S.-W.; Huang, B.-R.; Liu, Y.-S.; Lin, H.-Y.; Chen, C.-C.; Tsai, C.-F.; Lu, D.-Y.; Lin, C. Differential Characterization of Temozolomide-Resistant Human Glioma Cells. Int. J. Mol. Sci. 2018, 19, 127.
Lai S-W, Huang B-R, Liu Y-S, Lin H-Y, Chen C-C, Tsai C-F, Lu D-Y, Lin C. Differential Characterization of Temozolomide-Resistant Human Glioma Cells. International Journal of Molecular Sciences. 2018; 19(1):127.Chicago/Turabian Style
Lai, Sheng-Wei; Huang, Bor-Ren; Liu, Yu-Shu; Lin, Hsiao-Yun; Chen, Chun-Chuan; Tsai, Cheng-Fang; Lu, Dah-Yuu; Lin, Chingju. 2018. "Differential Characterization of Temozolomide-Resistant Human Glioma Cells." Int. J. Mol. Sci. 19, no. 1: 127.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.